Thursday 9 November 2017
1100 ET; 1600 GMT
The development of human iPSC technology offers researchers the ability to more accurately generate physiologically relevant models of disease and normal tissues in the laboratory. Advances in iPSC generation have allowed many laboratories to make their own cell lines; however, researchers rarely have the resources needed to establish stocks, undertake quality control and share their own de novo iPSC cell lines with other laboratories. A pre-existing and established iPSC collection therefore allows iPSC researchers to obtain “off the shelf” access to a large, robust and reliable supply of iPS cell lines that represent diverse donor to donor variability and which include disease status normal controls and gene edited cell lines. iPSCs from ECACC are standardized and quality controlled and have the benefit of coming from a trusted and internationally recognized collection with worldwide distribution.
You will learn about the:
The speaker is Sharon Bahia - Product and Distributor Manager (ECACC)
|Sharon has worked in the field of toxicology for over 15 years and with stem cells for the past 9 years. She has extensive knowledge of undertaking research in hospitals, academic laboratories, research institutes and pharmaceutical companies to better understand disease pathophysiology, investigate drug induced toxicity and develop personalised medicinal therapies. She is passionate about advising researchers on developing better in vitro models and over the last year Sharon has played a key role in the introduction and development ECACC's range of iPS cell lines|
Please confirm your country of origin from the list below.